NDLI: Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Mascarenhas, John
Description	Author Affiliation: Mascarenhas J ( Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.)
Abstract	Myelofibrosis (MF) is complex at the pathobiologic level and heterogeneous at the clinical level. The advances in molecular characterization of MF provide important insight into the mechanisms driving this chronic myeloid malignancy, refine risk stratification, offer novel therapeutic targets, and serve to measure therapeutic response. Although JAK2 inhibition has been the focus of laboratory and clinical efforts over the last decade, current experimental therapeutic approaches have broadened to include inhibitors of key alternative signaling pathways, epigenetic modulators, anti-fibrotics, and immunotherapies. Based on compelling preclinical rationale, a number of JAK2 inhibitor based combination therapies are now actively being evaluated in the clinic with the goal of disease course modification. The role and timing of hematopoietic stem cell transplant (HSCT) for MF has been challenged with the availability of commercial ruxolitinib and the plethora of experimental treatment options that exist. Integration of preconditioning JAK2 inhibition, reduced intensity conditioning regimens, and alternative donor sources are all being explored in an attempt to optimize this potentially curative modality. This review will summarize modern MF risk stratification, current clinical research approaches to chronic and advance phase MF focusing on novel agents alone and in combination, and update the reader on new directions in HSCT.
File Format	HTM / HTML
ISSN	10245332
Volume Number	2015
e-ISSN	16078454
Journal	Hematology
Language	English
Publisher	Taylor & Francis
Publisher Date	2015-01-01
Publisher Place	United States
Access Restriction	Subscribed
Subject Keyword	Discipline Hematology Hematopoietic Stem Cell Transplantation Methods Primary Myelofibrosis Therapy Antineoplastic Combined Chemotherapy Protocols Therapeutic Use Clinical Trials As Topic Hematologic Neoplasms Hematology Humans Immunotherapy Janus Kinase 2 Antagonists & Inhibitors Ligands Protein Kinase Inhibitors Pyrazoles Remission Induction Risk Signal Transduction Drug Effects Transplantation Conditioning Treatment Outcome Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Hematology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in